SCHEMBL4094497

SCHEMBL4094497

CCCOC(=O)c1c(N)sc2c1CCOC2

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.68
ALDH1A1 P00352 10/20 0.68
MEN1 O00255 4/20 0.68
KMT2A Q03164 4/20 0.68
GAA P10253 8/20 0.53
HPGD P15428 6/20 0.53
KDM4E B2RXH2 4/20 0.53
HSD17B10 Q99714 4/20 0.53
ALOX15 P16050 3/20 0.53
MAPK1 P28482 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.50
ADORA1 P30542 4/20 0.49
TSHR P16473 1/20 0.48
ALOX12 P18054 1/20 0.48
GRM6 O15303 1/20 0.43
POLB P06746 1/20 0.42
RECQL P46063 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3495630 0.90 MAPT (0.67) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL4090770 0.84 ALDH1A1 (0.49) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL8203239 0.80 MAPT (0.72) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL13768570 0.79 MAPT (0.67) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL6315716 0.79 CXCR2 (0.54) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL3761338 0.79 HSD17B10 (0.67) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL15199361 0.78 PTPRC (0.47) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL3452996 0.76 ALDH1A1 (0.60) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL3500340 0.76 PTPRC (0.58) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL14641131 0.74 ALDH1A1 (0.80) MAPTALDH1A1MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338623-B2 N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants ABBVIE INC. (US) 2012-12-25 US disclosed
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, GPR18 MAPT 2527/4885ALDH1A1 1504/4885MEN1 3065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.